ArticleCancer cell2014

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.

Matthew S Zabriskie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.